The rapid evolution of CRISPR/Cas genome editing has redefined the possibilities of cellular and gene therapy, enabling ...

Global clinical-stage biotech company HuidaGene Therapeutics has received FDA clearance to move forward with its application for its investigational drug, a CRISPR/Cas13 RNA-editing therapy to treat ...

Now, following up on that success, a large Chinese collaboration has followed up with a description of an improved gene ...

The global cell therapy technologies market is set to grow from USD 4.41 billion in 2025 to USD 7.91 billion by 2030, ...

CRISPR gene editing machinery holds the potential to transform the treatment of numerous diseases, but it requires effective delivery systems to get into tissues and ...

At the heart of this technology is the Cas9 protein, often likened to molecular scissors, capable of cutting strands of DNA at specific locations dictated by a single guide RNA. With this mechanism, ...

CRISPR gene editing has revolutionized the field of molecular biology, offering precise, efficient, and versatile tools for genome modification. The technology has rapidly evolved beyond the original ...

On October 22, Nobel Prize–winning biochemist Dr. Jennifer Doudna dined with supporters of UCSB Arts & Lectures (A&L) and the Cancer Foundation of S.B. (CFSB). The intimate, al fresco dinner party at ...

Trace the timeline of CRISPR-Cas9 from its 2012 discovery to the latest AI-driven advancements and "N-of-1" clinical therapies.